1	not receive an unlicensed investigational agent drug device or blood-derived product within 30 day prior to randomization and may not receive such an investigational agent in the 30 day post-randomization note investigational use for treatment of tma of a license immunomodulator e.g. rituximab be|tma[247,250]|||||||30 day[92,98]|||89775|89775|tma
1	not receive an unlicensed investigational agent drug device or blood-derived product within 30 day prior to randomization and may not receive such an investigational agent in the 30 day post-randomization note investigational use for treatment of tma of a license immunomodulator e.g. rituximab be|tma[92,98]||||||||||89775|89775|tma
1	not receive an unlicensed investigational agent drug device or blood-derived product within 30 day prior to randomization and may not receive such an investigational agent in the 30 day post-randomization note investigational use for treatment of tma of a license immunomodulator e.g. rituximab be|immunomodulator[264,279]||||||||||491496|491496|immunomodulator
1	not receive an unlicensed investigational agent drug device or blood-derived product within 30 day prior to randomization and may not receive such an investigational agent in the 30 day post-randomization note investigational use for treatment of tma of a license immunomodulator e.g. rituximab be|rituximab[285,294]|||||||||C0393022|121191|121191|rituximab
